Healthcare / Drug Manufacturers - Specialty & GenericMilan
$88.70
+1.20 (+1.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $16.2M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
71/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$849M
P/E
40.3x
↑EV/EBITDA
24.9x
↑ROE
28.0%
↑Gross Margin
77.4%
↑Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.8%
FCF CAGR
—
FCF margin
12.4%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $132.9M · net income $20.0M · FCF $16.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $132.9M | $132.9M | $116.8M | $101.4M | $83.4M |
| Net Income | $20.0M | $20.0M | $16.6M | $12.8M | $15.0M |
| EBITDA | $34.3M | $34.3M | $32.2M | $27.2M | $24.6M |
| EPS | 2.09 | 2.09 | 1.73 | 1.33 | 1.56 |
| Gross Margin | 77.4% | 77.4% | 77.8% | 70.7% | 73.7% |
| Operating Margin | 22.8% | 22.8% | 24.1% | 23.3% | 27.9% |
| Net Margin | 15.0% | 15.0% | 14.2% | 12.7% | 18.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.39 | 0.51 | 0.35 |
| Current Ratio | 2.38 | 2.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.4M | $16.4M | $16.2M | $-1.2M | $-8.7M |
| Returns | |||||
| ROE | 28.0% | 28.0% | 26.7% | 23.6% | 29.5% |
| Valuation | |||||
| P/E | 40.32 | 40.32 | 31.04 | 42.11 | 41.03 |
| EV/EBITDA | 24.88 | 24.88 | 16.31 | 20.21 | 24.96 |
| P/B | 11.92 | 11.92 | 8.29 | 9.93 | 12.15 |
| Growth & Yield | |||||
| Revenue Growth | 13.8% | 13.8% | 15.1% | 21.6% | — |
| EPS Growth | 20.8% | 20.8% | 30.1% | -14.7% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
55.6%
EPS terminal req.
$7.87
Spread vs growth
-34.8%
5Y implied EPS CAGR
35.4%
EPS terminal req.
$9.52
Spread vs growth
-14.6%
10Y implied EPS CAGR
22.1%
EPS terminal req.
$15.34
Spread vs growth
-1.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+82.7%
Start / end P/E
28.9x → 43.3x
EPS bridge
1.73 → 2.09
Residual
+10.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.